糖尿病ケア機器市場規模、シェア、動向、2030年までの世界予測

糖尿病ケア機器市場 – 製品タイプ（血糖モニタリング（CGM）、インスリン注入装置（インスリンポンプ（テザー）、インスリンペン、ペン型注射針）、用途）疾患タイプ（タイプ1、タイプ2）、エンドユーザー（在宅ケア/セルフケア） – 2030年までの世界予測

世界の糖尿病ケア機器市場は、予測期間中に年平均成長率12.3%で成長し、2025年の343億米ドルから2030年には612億米ドルに達すると予測されています。

運動不足、肥満、食習慣の変化を背景に糖尿病の罹患率が増加しており、糖尿病ケアのための効果的なモニタリング・管理ツールの需要が大幅に高まっています。2型糖尿病とその合併症にかかりやすい高齢者人口の増加も、血糖値モニタリング機器の需要をさらに押し上げています。さらに、予防医療への意識の高まりと関心の高まりにより、早期診断と自己管理ツールの利用が促進され、家庭用機器の利用が拡大しています。技術の進歩も、これらの機器を患者と医療従事者の双方にとって魅力的なものにしています。しかし、機器の高価格や、特定の市場では消費者の受容度や遵守率が低いことから、市場への普及は限定的になる可能性があります。

本レポートは、糖尿病ケア機器市場の分析を提供し、流通チャネル、地域、適応症、製品タイプなど、様々なセグメントにおける市場規模と将来の成長可能性の推定に重点を置いています。さらに、主要企業の競合分析も掲載しており、企業概要、製品・サービス内容、最近の動向、主要な市場インサイト戦略などを詳細に解説しています。

本レポートは、糖尿病ケア機器業界のマーケットリーダーと新規参入企業の両方にとって貴重な洞察を提供し、市場全体とそのサブセグメントの推定収益数値を示しています。ステークホルダーが競争環境を理解し、事業のポジショニングを改善し、効果的な市場開拓戦略を策定するのに役立ちます。さらに、主要な市場推進要因、制約要因、課題、そして機会に焦点を当て、ステークホルダーが市場の現状を評価するのに役立ちます。

The global diabetes care devices market is projected to reach 61.2 billion in 2030 from USD 34.3 billion in 2025, at a CAGR of 12.3% during the forecast period.

The rising prevalence of diabetes, driven by sedentary lifestyles, obesity, and changes in dietary habits, is significantly increasing the demand for effective monitoring and management tools for diabetes care. The growing geriatric population, which is more susceptible to type 2 diabetes and its complications, further boosts the demand for glucose monitoring devices. Additionally, increased awareness and a greater focus on preventive healthcare are encouraging early diagnosis and self-management tools, which are enhancing the use of home-based devices. Technological advancements also make these devices more appealing to both patients and healthcare providers. Wider market adoption may be limited by the high cost of devices and, in certain markets, low consumer acceptance or adherence.

By product type, the blood glucose monitoring segment is expected to account for the largest share of the global diabetes care devices market.

The global diabetes care devices market is divided into three main segments: blood glucose monitoring systems, insulin delivery devices, and diabetes management mobile applications. The blood glucose monitoring system segment holds the largest market share due to its strong functional advantages and medical support. These devices provide accurate real-time tracking, which helps prevent complications. Rising diabetes prevalence, physician recommendations, and innovations like smartphone integration further increase home adoption settings.

By patient care settings, the self/home healthcare segment is expected to account for the largest share of the global diabetes care devices market.

The global diabetes care devices market is segmented by patient care settings into the following categories: self/home healthcare and hospitals & diabetes specialty clinics. Among these, the self/home healthcare segment is expected to hold the largest market share. The increasing demand for convenient, cost-effective devices is driving growth in this area. Many people rely on self-testing devices, such as continuous blood glucose monitors, which reduce the need for clinical visits. Rising awareness of preventive care, advancements in both portable and connected technologies, and an increasing geriatric population, which is more susceptible to type 2 diabetes, are fueling the growth in demand for self/homecare devices.

By disease type, the type 2 diabetes segment is expected to account for the largest share of the global diabetes care devices market.

This dominance is mainly driven by lifestyle-related risk factors such as sedentary behavior, dietary habits, and increasing obesity, which make type 2 diabetes more prevalent in the population. The rise in obesity, fueled by high-calorie diets, processed foods, and physical inactivity, is the primary contributor to its rapid growth. Urbanization and modernization have further reduced daily physical activity while increasing access to fast food, leading to rising rates across both developed and developing countries. The disease is also strongly age-related, with older adults being more susceptible, and as global populations age, the prevalence naturally continues to rise.

The diabetes care devices market in the Asia Pacific is expected to grow at the highest CAGR during the forecast period.

The rapid rise in diabetes cases and the increasing demand for advanced diabetes care are driving a strong need for diabetes care devices in the Asia Pacific region. Additionally, global leaders in diabetes care products are expanding their footprint in the Asia Pacific by launching advanced formulations and digitally integrated diabetes care devices.

A breakdown of the primary participants (supply side) for the diabetes care devices  market referred to in this report is provided below:

• By Company Type: Tier 1 (30%), Tier 2 (35%), and Tier 3 (35%)
• By Designation: C-level Executives (20%), Directors (35%), and Others (45%)
• By Region: North America (30%), Europe (25%), Asia Pacific (20%), Latin America (20%), Middle East & Africa (2%), GCC Countries (3%)

Prominent players in the diabetes care devices market include F. Hoffmann Roche Ltd (Switzerland), Abbott Laboratories (US), Medtronic (Ireland), Dexcom (US), Insulet Corporation (US), B Braun Se (Germany), Embecta Corp (US), Nipro (Japan), Senseonics (US), Ypsomed (Switzerland), i-Sens, Inc (South Korea), Tandem Diabetes Care, Inc (US), ACON LABORATORIES, INC (US), ARKRAY, INC(Japan), Terumo Corporation (Japan), Sinocare Inc (Japan), Waveform Diabetes (AgaMatrix) (US), Lifescan IP Holdings (US), SD Biosensor, Inc (South Korea), DeBiotech SA. (Switzerland), Sungshim Medical Co, Ltd (South Korea), Sooil Developments Co., Ltd (South Korea), Hindustan syringes and medical devices (India), Microgene Diagnostic Systems Pvt Ltd (India), Rossmax International Ltd (Taiwan)

Research Coverage

The report provides an analysis of the diabetes care devices market, focusing on estimating the market size and potential for future growth across various segments, including distribution channels, regions, indications, and product types. Additionally, the report features a competitive analysis of the key players in the market, detailing their company profiles, product and service offerings, recent developments, and key market insights strategies.

Reasons to Buy the Report

The report offers valuable insights for both market leaders and new entrants in the diabetes care devices industry, providing estimated revenue figures for the entire market and its subsegments. It helps stakeholders understand the competitive landscape, allowing them to better position their businesses and develop effective go-to-market strategies. Additionally, the report emphasizes key market drivers, restraints, challenges, and opportunities, assisting stakeholders in assessing the current state of the market.

This report provides insights into the following pointers:

Analysis of key drivers (growing burden of diabetes care globally, rising geriatric population, increasing awareness and preventive healthcare focus, technological advancements), restraints (high cost of innovative diabetes devices, limited awareness in emerging markets), opportunities (enhanced diabetes management with advanced patient-implantable CGM devices) and challenges (limited sensor durability leading to repeated and costly replacements, high cost and socio-economic disparities in access to devices).

• Market Penetration: This report provides detailed information on the product portfolios offered by major players in the global diabetes care devices market. It covers various segments, including product types, patient care settings, and regions.
• Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global diabetes care devices market.
• Market Development: Thorough knowledge and analysis of the profitable rising markets by product types, patient care settings, disease type, and regions.
• Market Diversification: Comprehensive information about newly launched products and services, expanding markets, current advancements, and investments in the global diabetes care devices market.
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products and services, and capacities of the major competitors in the global diabetes care devices market.

Table of Contents

1               INTRODUCTION              29

1.1           STUDY OBJECTIVES       29

1.2           MARKET DEFINITION   29

1.3           STUDY SCOPE   30

1.3.1        MARKET SEGMENTATION & REGIONAL SCOPE 30

1.3.2        INCLUSIONS & EXCLUSIONS       31

1.3.3        YEARS CONSIDERED      32

1.3.4        CURRENCY CONSIDERED            32

1.4           STAKEHOLDERS               33

1.5           SUMMARY OF CHANGES               33

1.5.1        REFINEMENTS IN SCOPE              33

1.5.2        COVERAGE OF NEW PLAYERS    33

1.5.3        ADDITION OF SEGMENTS            33

1.5.4        UPDATED MARKET DEVELOPMENTS OF PROFILED PLAYERS              34

1.5.5        UPDATED FINANCIAL INFORMATION/PRODUCT PORTFOLIOS OF PLAYERS           34

1.5.6        UPDATED GEOGRAPHIC ANALYSIS         34

1.5.7        IMPACT OF AI   34

1.5.8        IMPACT OF US TARIFF  34

2               RESEARCH METHODOLOGY       35

2.1           RESEARCH DATA              35

2.1.1        SECONDARY DATA          36

2.1.1.1    Key sources of secondary data            36

2.1.1.2    Key data from secondary sources       37

2.1.2        PRIMARY DATA 37

2.1.2.1    Key primary sources             37

2.1.2.2    Key objectives of primary research    38

2.1.2.3    Key data from primary sources           38

2.1.2.4    Key industry insights           39

2.2           MARKET SIZE ESTIMATION         40

2.2.1        REVENUE SHARE ANALYSIS         40

2.2.2        BOTTOM-UP APPROACH (SUPPLY-SIDE ANALYSIS)                 43

2.2.3        COMPANY PRESENTATIONS & PRIMARY INTERVIEWS                 43

2.2.4        TOP-DOWN APPROACH                45

2.3           DATA TRIANGULATION                46

2.4           MARKET SHARE ESTIMATION    47

2.5           STUDY ASSUMPTIONS  47

2.6           RESEARCH LIMITATIONS             47

2.6.1        SCOPE-RELATED LIMITATIONS                 47

2.6.2        METHODOLOGY-RELATED LIMITATIONS           47

2.7           RISK ANALYSIS  48

3               EXECUTIVE SUMMARY  49

4               PREMIUM INSIGHTS       52

4.1           DIABETES CARE DEVICES MARKET OVERVIEW  52

4.2           ASIA PACIFIC: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE AND

COUNTRY (2024)               53

4.3           DIABETES CARE DEVICES MARKET: GEOGRAPHICAL MIX        54

4.4           DIABETES CARE DEVICES MARKET: REGIONAL MIX                 54

4.5           DIABETES CARE DEVICES MARKET: DEVELOPED VS. EMERGING MARKETS    55

5               MARKET OVERVIEW       56

5.1           INTRODUCTION              56

5.2           MARKET DYNAMICS       56

5.2.1        DRIVERS               57

5.2.1.1    Surging global diabetes patient population requiring continuous care         57

5.2.1.2    Rapidly growing geriatric population                 57

5.2.1.3    Increasing efforts toward public awareness and preventive healthcare               57

5.2.1.4    Rapid technological advancements in diabetes care        58

5.2.2        RESTRAINTS      58

5.2.2.1    High cost of advanced diabetes care devices    58

5.2.2.2    Limited awareness in emerging healthcare markets       58

5.2.3        OPPORTUNITIES              59

5.2.3.1    Enhanced diabetes management with advanced patient-implantable continuous glucose monitoring devices       59

5.2.4        CHALLENGES    59

5.2.4.1    Limited sensor durability with repeated and costly replacements                 59

5.2.4.2    High cost and socio-economic disparities in access to diabetes

care devices           60

5.3           INDUSTRY TRENDS         60

5.3.1        RISING ADOPTION OF DIGITAL HEALTH SOLUTIONS AND TELEMEDICINE INTEGRATION IN DIABETES CARE                 60

5.3.2        ACCELERATING SHIFT TOWARD HOME-BASED, PATIENT-CENTRIC, AND

SELF-MANAGED DIABETES CARE              60

5.4           TECHNOLOGY ANALYSIS             61

5.4.1        KEY TECHNOLOGIES     61

5.4.1.1    Implantable sensors              61

5.4.1.2    Smart automated insulin pumps        61

5.4.2        COMPLEMENTARY TECHNOLOGIES       61

5.4.2.1    Telehealth services               61

5.4.3        ADJACENT TECHNOLOGIES       62

5.4.3.1    Cutting-edge and smartphone-enabled diabetes self-management technologies  62

5.5           PRICING ANALYSIS          62

5.5.1        AVERAGE SELLING PRICE TREND OF DIABETES CARE DEVICES,

BY KEY PLAYER, 2022–2024            62

5.5.2        AVERAGE SELLING PRICE TREND OF DIABETES CARE DEVICES, BY REGION, 2022–2024                 62

5.6           ECOSYSTEM ANALYSIS  63

5.6.1        ROLE IN ECOSYSTEM     64

5.7           REIMBURSEMENT SCENARIO ANALYSIS                 65

5.8           VALUE CHAIN ANALYSIS               65

5.9           PORTER’S FIVE FORCES ANALYSIS           66

5.9.1        INTENSITY OF COMPETITIVE RIVALRY 68

5.9.2        BARGAINING POWER OF SUPPLIERS       68

5.9.3        BARGAINING POWER OF BUYERS             68

5.9.4        THREAT OF SUBSTITUTES          68

5.9.5        THREAT OF NEW ENTRANTS      69

5.10         KEY STAKEHOLDERS & BUYING CRITERIA            69

5.10.1      KEY STAKEHOLDERS IN BUYING PROCESS           69

5.10.2      KEY BUYING CRITERIA  70

5.11         TRADE ANALYSIS             71

5.11.1      IMPORT DATA FOR HS CODE 9027, 2020–2024      71

5.11.2      EXPORT DATA FOR HS CODE 9027, 2020–2024      71

5.12         REGULATORY ANALYSIS               72

5.12.1      REGULATORY FRAMEWORK       72

5.12.1.1  North America      72

5.12.1.1.1                US           72

5.12.1.1.2                Canada   72

5.12.1.2  Europe   72

5.12.1.3  Asia Pacific            72

5.12.1.3.1                China      72

5.12.1.3.2                Japan      72

5.12.1.3.3                India       73

5.12.1.4  Latin America       73

5.12.1.4.1                Brazil      73

5.12.1.4.2                Mexico   73

5.12.1.5  Middle East           73

5.12.1.6  Africa      74

5.12.2      REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS             74

5.13         PATENT ANALYSIS          76

5.13.1      PATENT PUBLICATION TRENDS FOR DIABETES CARE DEVICES MARKET            76

5.13.2      JURISDICTION ANALYSIS: TOP APPLICANTS FOR PATENTS IN

DIABETES CARE DEVICES             77

5.13.3      LIST OF MAJOR PATENTS             78

5.14         KEY CONFERENCES & EVENTS, 2025–2026              79

5.15         ADJACENT MARKET ANALYSIS  79

5.16         TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES       80

5.17         UNMET NEEDS/END-USER EXPECTATIONS         80

5.17.1      UNMET NEEDS 80

5.17.2      END-USER EXPECTATIONS         81

5.18         IMPACT OF AI/GEN AI IN DIABETES CARE DEVICES MARKET               81

5.19         CASE STUDY ANALYSIS 83

5.19.1      LONG-TERM GLUCOSE MONITORING FOR SENSITIVE SKIN PATIENTS USING SENSEONICS’ EVERSENSE E3 IMPLANTABLE SENSORS               83

5.19.2      ENHANCING PATIENT ADHERENCE AND GLYCEMIC CONTROL USING ABBOTT’S FREESTYLE LIBRE 2 CGM   83

5.19.3      MEDTRONIC MINIMED INSULIN PUMP TO ENHANCE GLUCOSE CONTROL AND IMPROVE DAILY MANAGEMENT FOR PEOPLE WITH DIABETES             84

5.20         INVESTMENT & FUNDING SCENARIO     84

5.21         IMPACT OF 2025 US TARIFF ON DIABETES CARE DEVICES MARKET            85

5.21.1      INTRODUCTION              85

5.21.2      KEY TARIFF RATES          86

5.21.3      PRICE IMPACT ANALYSIS             86

5.21.4      IMPACT ON END-USE INDUSTRIES          87

6               DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE                 88

6.1           INTRODUCTION              89

6.2           BLOOD GLUCOSE MONITORING SYSTEMS          90

6.2.1        SELF-MONITORING BLOOD GLUCOSE SYSTEMS                 92

6.2.1.1    Need for self-monitoring in type 1 and type 2 diabetes management to propel market growth               92

6.2.2        CONTINUOUS GLUCOSE MONITORING SYSTEMS                 93

6.2.2.1    Technological advancements in continuous glucose monitoring systems to track trends and enhance diabetes management          93

6.2.3        TEST STRIPS/TEST PAPERS         95

6.2.3.1    Shift toward non-invasive methods for blood glucose monitoring to restrain market growth    95

6.2.4        LANCETS/LANCING DEVICES    96

6.2.4.1    Need for infection and accidental pricking to increase popularity of safety lancets/lancing devices        96

6.3           INSULIN DELIVERY DEVICES      97

6.3.1        INSULIN PUMPS & ACCESSORIES              99

6.3.1.1    Tethered pumps   101

6.3.1.1.1 Increase in collaborations and partnerships among companies to develop integrated insulin systems    101

6.3.1.2    Tubeless insulin pumps       102

6.3.1.2.1 Use of artificial intelligence to replace traditional vial-syringe combinations with tubeless pumps    102

6.3.2        INSULIN PENS   104

6.3.2.1    Reusable insulin pens           106

6.3.2.1.1 Technology innovations and cost-effectiveness to boost market growth    106

6.3.2.2    Disposable insulin pens       107

6.3.2.2.1 Ease of use, accurate dose measurement, and built-in cartridges to propel segment growth   107

6.3.3        PEN NEEDLES   108

6.3.3.1    Reduced chances of infection and accidental pricking to augment market growth       108

6.3.4        INSULIN SYRINGES & NEEDLES 110

6.3.4.1    Safety concerns and need for affordable alternatives to limit market growth       110

6.3.5        OTHER INSULIN DELIVERY DEVICES      111

6.4           DIABETES MANAGEMENT MOBILE APPLICATIONS                 114

6.4.1        INCREASING PREVALENCE OF DIABETES AND RISING ADOPTION OF BLOOD GLUCOSE TRACKING APPLICATIONS TO DRIVE MARKET 114

7               DIABETES CARE DEVICES MARKET, BY DISEASE TYPE                 115

7.1           INTRODUCTION              116

7.2           TYPE 1 DIABETES            116

7.2.1        CHRONIC NATURE OF TYPE 1 DIABETES AND NEED

FOR IMPROVED DIAGNOSIS TO AID MARKET GROWTH                 116

7.3           TYPE 2 DIABETES            118

7.3.1        RISING BURDEN OF TYPE 2 DIABETES TO INCREASE NEED

FOR SCALABLE CARE DEVICE SOLUTIONS           118

8               DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS            120

8.1           INTRODUCTION              121

8.2           SELF/HOME HEALTHCARE          122

8.2.1        INCREASING AFFORDABILITY OF SELF-MONITORING SYSTEMS

AND INSULIN DELIVERY DEVICES TO FUEL PREFERENCE                 122

8.3           HOSPITALS & DIABETES SPECIALTY CLINICS     124

8.3.1        RISING DEMAND FOR POINT-OF-CARE TESTING IN HOSPITALS

TO BOOST MARKET GROWTH   124

9               DIABETES CARE DEVICES MARKET, BY REGION 126

9.1           INTRODUCTION              127

9.2           NORTH AMERICA             128

9.2.1        MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 128

9.2.2        US           132

9.2.2.1    US to dominate North American diabetes care devices market during forecast period          132

9.2.3        CANADA               135

9.2.3.1    High prevalence of diabetes and supportive government disease management initiatives to spur market growth                135

9.3           EUROPE               138

9.3.1        MACROECONOMIC OUTLOOK FOR EUROPE      138

9.3.2        GERMANY           142

9.3.2.1    Advanced healthcare infrastructure to drive adoption of innovative diabetes care devices        142

9.3.3        UK          145

9.3.3.1    Increased government support and improved research funding to propel market growth           145

9.3.4        FRANCE                148

9.3.4.1    Substantial national spending on diabetes management and robust healthcare infrastructure to aid market growth   148

9.3.5        ITALY    151

9.3.5.1    High diabetes-related mortality and increased public investment to augment market growth  151

9.3.6        SPAIN    153

9.3.6.1    Minimal co-payments and full reimbursement to drive market                 153

9.3.7        REST OF EUROPE             156

9.4           ASIA PACIFIC     159

9.4.1        MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 159

9.4.2        CHINA  163

9.4.2.1    Huge diabetic population and high government healthcare spending to spur market growth         163

9.4.3        JAPAN   166

9.4.3.1    Increased geriatric population and supportive healthcare policies to support market growth    166

9.4.4        INDIA    169

9.4.4.1    Rise in diabetes cases and affordable local manufacturing to fuel diabetes care devices demand             169

9.4.5        AUSTRALIA         172

9.4.5.1    Comprehensive government-backed initiatives and subsidies to support market growth        172

9.4.6        SOUTH KOREA  175

9.4.6.1    Rise in diabetes cases and strong government healthcare support to boost market growth        175

9.4.7        REST OF ASIA PACIFIC   178

9.5           LATIN AMERICA                181

9.5.1        MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 181

9.5.2        BRAZIL 185

9.5.2.1    Increasing adoption of advanced diabetes monitoring and management solutions to aid market growth   185

9.5.3        MEXICO                188

9.5.3.1    Supportive regulatory frameworks and high burden of diabetes to propel market growth           188

9.5.4        REST OF LATIN AMERICA             191

9.6           MIDDLE EAST & AFRICA                194

9.6.1        INCREASING AWARENESS OF EARLY DIAGNOSIS AND GLYCEMIC CONTROL FOR DIABETES MANAGEMENT TO FAVOR MARKET GROWTH          194

9.6.2        MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 194

9.7           GCC COUNTRIES              197

9.7.1        RISE IN DIABETES PREVALENCE AND HIGH PER CAPITA HEALTHCARE EXPENDITURE TO DRIVE MARKET             197

9.7.2        MACROECONOMIC OUTLOOK FOR GCC COUNTRIES                 198

10            COMPETITIVE LANDSCAPE         201

10.1         INTRODUCTION              201

10.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            201

10.2.1      OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DIABETES CARE DEVICES MARKET    202

10.3         REVENUE ANALYSIS, 2020–2024  203

10.4         MARKET SHARE ANALYSIS, 2024                 203

10.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 206

10.5.1      STARS   206

10.5.2      EMERGING LEADERS     206

10.5.3      PERVASIVE PLAYERS      206

10.5.4      PARTICIPANTS 206

10.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         208

10.5.5.1  Company footprint               208

10.5.5.2  Region footprint   209

10.5.5.3  Product type footprint         210

10.5.5.4  Patient care settings footprint            211

10.5.5.5  Disease type footprint          212

10.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        213

10.6.1      PROGRESSIVE COMPANIES         213

10.6.2      RESPONSIVE COMPANIES            213

10.6.3      DYNAMIC COMPANIES  213

10.6.4      STARTING BLOCKS         213

10.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 215

10.6.5.1  Detailed list of key startups/SMEs    215

10.6.5.2  Competitive benchmarking of key startups/SMEs          215

10.7         COMPANY VALUATION & FINANCIAL METRICS 216

10.7.1      FINANCIAL METRICS      216

10.7.2      COMPANY VALUATION 216

10.8         BRAND/PRODUCT COMPARISON             217

10.9         R&D EXPENDITURE OF KEY PLAYERS     218

10.10       COMPETITIVE SCENARIO             218

10.10.1   PRODUCT LAUNCHES AND APPROVALS               218

10.10.2   DEALS  219

10.10.3   EXPANSIONS     220

10.10.4   OTHER DEVELOPMENTS              220

11            COMPANY PROFILES      221

11.1         KEY PLAYERS     221

11.1.1      F. HOFFMAN-LA ROCHE LTD.    221

11.1.1.1  Business overview 221

11.1.1.2  Products/Solutions offered 222

11.1.1.3  Recent developments           223

11.1.1.3.1                Product launches & approvals            223

11.1.1.3.2                Deals      224

11.1.1.3.3                Expansions             224

11.1.1.4  MnM view              225

11.1.1.4.1                Right to win           225

11.1.1.4.2                Strategic choices   225

11.1.1.4.3                Weaknesses & competitive threats     225

11.1.2      ABBOTT               226

11.1.2.1  Business overview 226

11.1.2.2  Products/Solutions offered 228

11.1.2.3  Recent developments           229

11.1.2.3.1                Product launches & approvals            229

11.1.2.3.2                Deals      230

11.1.2.3.3                Expansions             231

11.1.2.3.4                Other developments             231

11.1.2.4  MnM view              231

11.1.2.4.1                Right to win           231

11.1.2.4.2                Strategic choices   232

11.1.2.4.3                Weaknesses & competitive threats     232

11.1.3      DEXCOM, INC.   233

11.1.3.1  Business overview 233

11.1.3.2  Products/Solutions offered 234

11.1.3.3  Recent developments           235

11.1.3.3.1                Product launches & approvals            235

11.1.3.3.2                Deals      236

11.1.3.3.3                Expansions             236

11.1.3.4  MnM view              237

11.1.3.4.1                Right to win           237

11.1.3.4.2                Strategic choices   237

11.1.3.4.3                Weaknesses & competitive threats     237

11.1.4      MEDTRONIC      238

11.1.4.1  Business overview 238

11.1.4.2  Products/Solutions offered 239

11.1.4.3  Recent developments           240

11.1.4.3.1                Product launches & approvals            240

11.1.4.3.2                Deals      241

11.1.4.3.3                Expansions             242

11.1.4.3.4                Other developments             242

11.1.4.4  MnM view              242

11.1.4.4.1                Right to win           242

11.1.4.4.2                Strategic choices   243

11.1.4.4.3                Weaknesses & competitive threats     243

11.1.5      B. BRAUN SE       244

11.1.5.1  Business overview 244

11.1.5.2  Products/Solutions offered 245

11.1.5.3  MnM view              246

11.1.5.3.1                Right to win           246

11.1.5.3.2                Strategic choices   246

11.1.5.3.3                Weaknesses & competitive threats     246

11.1.6      EMBECTA CORP.              247

11.1.6.1  Business overview 247

11.1.6.2  Products/Solutions offered 249

11.1.6.3  Recent developments           249

11.1.6.3.1                Product approvals 249

11.1.6.3.2                Deals      249

11.1.6.3.3                Expansions             250

11.1.6.3.4                Other developments             250

11.1.7      NIPRO   251

11.1.7.1  Business overview 251

11.1.7.2  Products/Solutions offered 252

11.1.7.3  Recent developments           253

11.1.7.3.1                Expansions             253

11.1.8      SENSEONICS      254

11.1.8.1  Business overview 254

11.1.8.2  Products/Solutions offered 255

11.1.8.3  Recent developments           256

11.1.8.3.1                Product launches & approvals            256

11.1.8.3.2                Deals      256

11.1.8.3.3                Other developments             257

11.1.9      YPSOMED            258

11.1.9.1  Business overview 258

11.1.9.2  Products/Solutions offered 259

11.1.9.3  Recent developments           260

11.1.9.3.1                Product launches & approvals            260

11.1.9.3.2                Deals      261

11.1.9.3.3                Expansions             262

11.1.9.3.4                Other developments             263

11.1.10   I-SENS, INC.        264

11.1.10.1                 Business overview 264

11.1.10.2                 Products/Solutions offered 265

11.1.10.3                 Recent developments           266

11.1.10.3.1             Product approvals 266

11.1.10.3.2             Deals      266

11.1.11   TANDEM DIABETES CARE, INC. 267

11.1.11.1                 Business overview 267

11.1.11.2                 Products/Solutions offered 268

11.1.11.3                 Recent developments           269

11.1.11.3.1             Product launches & approvals            269

11.1.11.3.2             Deals      270

11.1.12   INSULET CORPORATION              272

11.1.12.1                 Business overview 272

11.1.12.2                 Products/Solutions offered 273

11.1.12.3                 Recent developments           274

11.1.12.3.1             Product launches & approvals            274

11.1.12.3.2             Deals      276

11.1.12.3.3             Expansions             276

11.1.12.3.4             Other developments             277

11.1.13   ACON LABORATORIES, INC.        278

11.1.13.1                 Business overview 278

11.1.13.2                 Products/Solutions offered 278

11.1.14   ARKRAY, INC.     280

11.1.14.1                 Business overview 280

11.1.14.2                 Products/Solutions offered 280

11.1.14.3                 Recent developments           281

11.1.14.3.1             Product launches  281

11.1.15   TERUMO CORPORATION             282

11.1.15.1                 Business overview 282

11.1.15.2                 Products/Solutions offered 283

11.1.15.3                 Recent developments           284

11.1.15.3.1             Product launches  284

11.1.15.3.2             Deals      284

11.1.15.3.3             Expansions             285

11.1.15.3.4             Other developments             285

11.2         OTHER PLAYERS              286

11.2.1      SINOCARE           286

11.2.2      AGAMATRIX       288

11.2.3      LIFESCAN IP HOLDINGS, LLC     289

11.2.4      SD BIOSENSOR, INC.       290

11.2.5      DEBIOTECH S.A.               291

11.2.6      SUNGSHIM MEDICAL CO., LTD. 292

11.2.7      SOOIL DEVELOPMENTS CO., LTD.           293

11.2.8      HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.                 294

11.2.9      MICROGENE DIAGNOSTIC SYSTEMS (P) LTD.     295

11.2.10   ROSSMAX INTERNATIONAL LTD.             296

12            APPENDIX           297

12.1         DISCUSSION GUIDE        297

12.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                300

12.3         CUSTOMIZATION OPTIONS        302

12.4         RELATED REPORTS         302

12.5         AUTHOR DETAILS           303

LIST OF TABLES

TABLE 1                DIABETES CARE DEVICES MARKET: INCLUSIONS & EXCLUSIONS       31

TABLE 2                STANDARD CURRENCY CONVERSION RATES                 32

TABLE 3                STUDY ASSUMPTIONS IN DIABETES CARE DEVICES MARKET            47

TABLE 4                RISK ANALYSIS IN DIABETES CARE DEVICES MARKET               48

TABLE 5                AVERAGE SELLING PRICE TREND OF DIABETES CARE DEVICES, BY KEY PLAYER, 2022–2024 (USD)              62

TABLE 6                AVERAGE SELLING PRICE TREND OF DIABETES CARE, BY REGION,

2022–2024 (USD)                63

TABLE 7                DIABETES CARE DEVICES MARKET: ROLE IN ECOSYSTEM       64

TABLE 8                DIABETES CARE DEVICES MARKET: PORTER’S FIVE FORCES      67

TABLE 9                INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER               69

TABLE 10              KEY BUYING CRITERIA FOR MAJOR END USERS                 70

TABLE 11             IMPORT DATA FOR HS CODE 9027, BY COUNTRY, 2020–2024 (USD THOUSAND)      71

TABLE 12             EXPORT DATA FOR HS CODE 9027, BY COUNTRY, 2020–2024 (USD THOUSAND)      71

TABLE 13              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  74

TABLE 14              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  74

TABLE 15              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  75

TABLE 16              LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  76

TABLE 17              REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  76

TABLE 18              LIST OF MAJOR PATENTS IN DIABETES CARE DEVICES MARKET, 2022–2024       78

TABLE 19              DIABETES CARE DEVICES MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026                 79

TABLE 20              UNMET NEEDS IN DIABETES CARE DEVICES MARKET               80

TABLE 21              END-USER EXPECTATIONS IN DIABETES CARE DEVICES MARKET            81

TABLE 22              IMPACT OF AI/GEN AI IN DIABETES CARE DEVICES MARKET            82

TABLE 23              CASE STUDY 1: LONG-TERM GLUCOSE MONITORING FOR SENSITIVE SKIN PATIENTS USING SENSEONICS’ EVERSENSE E3 IMPLANTABLE SENSORS    83

TABLE 24              CASE STUDY 2: ENHANCING PATIENT ADHERENCE AND GLYCEMIC CONTROL USING ABBOTT’S FREESTYLE LIBRE 2 CGM              83

TABLE 25              CASE STUDY 3: MEDTRONIC MINIMED INSULIN PUMP TO ENHANCE GLUCOSE CONTROL AND IMPROVE DAILY MANAGEMENT FOR PEOPLE WITH DIABETES   84

TABLE 26              US-ADJUSTED RECIPROCAL TARIFF RATES                 86

TABLE 27              DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            89

TABLE 28              DIABETES CARE DEVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     90

TABLE 29              DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)            91

TABLE 30              DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 91

TABLE 31              SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            93

TABLE 32              CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            94

TABLE 33              TEST STRIPS/TEST PAPERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     96

TABLE 34              LANCETS/LANCING DEVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     97

TABLE 35              DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES,

BY TYPE, 2023–2030 (USD MILLION)         98

TABLE 36              DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               98

TABLE 37              INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)                99

TABLE 38              INSULIN PUMPS & ACCESSORIES MARKET, BY REGION,

2023–2030 (THOUSAND UNITS)  99

TABLE 39              INSULIN PUMPS & ACCESSORIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            100

TABLE 40              TETHERED INSULIN PUMPS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     101

TABLE 41              TUBELESS INSULIN PUMPS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     103

TABLE 42              INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 104

TABLE 43              INSULIN PENS MARKET, COUNTRY, 2023–2030 (USD MILLION) 105

TABLE 44              REUSABLE INSULIN PENS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     107

TABLE 45              DISPOSABLE INSULIN PENS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     108

TABLE 46              PEN NEEDLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109

TABLE 47              INSULIN SYRINGES & NEEDLES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            111

TABLE 48              OTHER INSULIN DELIVERY DEVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            113

TABLE 49              DIABETES CARE DEVICES MARKET FOR DIABETES MANAGEMENT MOBILE APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     114

TABLE 50              DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)                116

TABLE 51              TYPE 1 DIABETES CARE DEVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            117

TABLE 52              TYPE 2 DIABETES CARE DEVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            119

TABLE 53              DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS,

2023–2030 (USD MILLION)            121

TABLE 54              DIABETES CARE DEVICES MARKET FOR SELF/HOME HEALTHCARE, BY COUNTRY, 2023–2030 (USD MILLION)            123

TABLE 55              DIABETES CARE DEVICES MARKET FOR HOSPITAL & DIABETES SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)       125

TABLE 56              DIABETES CARE DEVICES MARKET, BY REGION, 2023–2030 (USD MILLION)            128

TABLE 57              NORTH AMERICA: DIABETES CARE DEVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            129

TABLE 58              NORTH AMERICA: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            130

TABLE 59              NORTH AMERICA: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)                130

TABLE 60              NORTH AMERICA: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 131

TABLE 61              NORTH AMERICA: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            131

TABLE 62              NORTH AMERICA: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION)                131

TABLE 63              NORTH AMERICA: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION)            132

TABLE 64              NORTH AMERICA: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            132

TABLE 65              US: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)          133

TABLE 66              US: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 133

TABLE 67              US: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION)            134

TABLE 68              US: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            134

TABLE 69              US: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 134

TABLE 70              US: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS,

2023–2030 (USD MILLION)            135

TABLE 71              US: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            135

TABLE 72              CANADA: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            136

TABLE 73              CANADA: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)       136

TABLE 74              CANADA: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES,

BY TYPE, 2023–2030 (USD MILLION)         137

TABLE 75              CANADA: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            137

TABLE 76              CANADA: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION)            137

TABLE 77              CANADA: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS,

2023–2030 (USD MILLION)            138

TABLE 78              CANADA: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            138

TABLE 79              EUROPE: DIABETES CARE DEVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            139

TABLE 80              EUROPE: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            139

TABLE 81              EUROPE: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)       140

TABLE 82              EUROPE: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES,

BY TYPE, 2023–2030 (USD MILLION)         140

TABLE 83              EUROPE: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            140

TABLE 84              EUROPE: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION)            141

TABLE 85              EUROPE: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS,

2023–2030 (USD MILLION)            141

TABLE 86              EUROPE: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            141

TABLE 87              GERMANY: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            142

TABLE 88              GERMANY: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)       143

TABLE 89              GERMANY: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES,

BY TYPE, 2023–2030 (USD MILLION)         143

TABLE 90              GERMANY: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            143

TABLE 91              GERMANY: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION)            144

TABLE 92              GERMANY: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION)                 144

TABLE 93              GERMANY: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            144

TABLE 94              UK: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            145

TABLE 95              UK: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 146

TABLE 96              UK: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES,

BY TYPE, 2023–2030 (USD MILLION)         146

TABLE 97              UK: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            146

TABLE 98              UK: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 147

TABLE 99              UK: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS,

2023–2030 (USD MILLION)            147

TABLE 100            UK: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            147

TABLE 101            FRANCE: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            148

TABLE 102            FRANCE: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)       149

TABLE 103            FRANCE: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES,

BY TYPE, 2023–2030 (USD MILLION)         149

TABLE 104            FRANCE: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            149

TABLE 105            FRANCE: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION)            150

TABLE 106            FRANCE: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS,

2023–2030 (USD MILLION)            150

TABLE 107            FRANCE: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            150

TABLE 108            ITALY: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            151

TABLE 109            ITALY: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 152

TABLE 110            ITALY: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES,

BY TYPE, 2023–2030 (USD MILLION)         152

TABLE 111            ITALY: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            152

TABLE 112            ITALY: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION)       153

TABLE 113            ITALY: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS,

2023–2030 (USD MILLION)            153

TABLE 114            ITALY: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            153

TABLE 115            SPAIN: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            154

TABLE 116            SPAIN: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 154

TABLE 117            SPAIN: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES,

BY TYPE, 2023–2030 (USD MILLION)         155

TABLE 118            SPAIN: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            155

TABLE 119            SPAIN: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION)       155

TABLE 120            SPAIN: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS,

2023–2030 (USD MILLION)            156

TABLE 121            SPAIN: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            156

TABLE 122            REST OF EUROPE: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            157

TABLE 123            REST OF EUROPE: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)                157

TABLE 124            REST OF EUROPE: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 158

TABLE 125            REST OF EUROPE: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            158

TABLE 126            REST OF EUROPE: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION)                158

TABLE 127            REST OF EUROPE: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION)            159

TABLE 128            REST OF EUROPE: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            159

TABLE 129            ASIA PACIFIC: DIABETES CARE DEVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            160

TABLE 130            ASIA PACIFIC: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            161

TABLE 131            ASIA PACIFIC: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)                161

TABLE 132            ASIA PACIFIC: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 162

TABLE 133            ASIA PACIFIC: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            162

TABLE 134            ASIA PACIFIC: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION)            162

TABLE 135            ASIA PACIFIC: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION)            163

TABLE 136            ASIA PACIFIC: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)          163

TABLE 137            CHINA: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            164

TABLE 138            CHINA: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 164

TABLE 139            CHINA: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES,

BY TYPE, 2023–2030 (USD MILLION)         165

TABLE 140            CHINA: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            165

TABLE 141            CHINA: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION)       165

TABLE 142            CHINA: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS,

2023–2030 (USD MILLION)            166

TABLE 143            CHINA: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            166

TABLE 144            JAPAN: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            167

TABLE 145            JAPAN: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 167

TABLE 146            JAPAN: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES,

BY TYPE, 2023–2030 (USD MILLION)         168

TABLE 147            JAPAN: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            168

TABLE 148            JAPAN: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION)       168

TABLE 149            JAPAN: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS,

2023–2030 (USD MILLION)            169

TABLE 150            JAPAN: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            169

TABLE 151            INDIA: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            170

TABLE 152            INDIA: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 170

TABLE 153            INDIA: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES,

BY TYPE, 2023–2030 (USD MILLION)         171

TABLE 154            INDIA: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            171

TABLE 155            INDIA: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION)       171

TABLE 156            INDIA: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS,

2023–2030 (USD MILLION)            172

TABLE 157            INDIA: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            172

TABLE 158            AUSTRALIA: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            173

TABLE 159            AUSTRALIA: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)       173

TABLE 160            AUSTRALIA: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION)            174

TABLE 161            AUSTRALIA: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            174

TABLE 162            AUSTRALIA: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION)            174

TABLE 163            AUSTRALIA: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION)                 175

TABLE 164            AUSTRALIA: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            175

TABLE 165            SOUTH KOREA: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            176

TABLE 166            SOUTH KOREA: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)                176

TABLE 167            SOUTH KOREA: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 177

TABLE 168            SOUTH KOREA: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            177

TABLE 169            SOUTH KOREA: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION)                177

TABLE 170            SOUTH KOREA: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION)            178

TABLE 171            SOUTH KOREA: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            178

TABLE 172            REST OF ASIA PACIFIC: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)            179

TABLE 173            REST OF ASIA PACIFIC: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)    179

TABLE 174            REST OF ASIA PACIFIC: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION)            180

TABLE 175            REST OF ASIA PACIFIC: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            180

TABLE 176            REST OF ASIA PACIFIC: INSULIN PENS MARKET, BY TYPE,

2023–2030 (USD MILLION)            180

TABLE 177            REST OF ASIA PACIFIC: DIABETES CARE DEVICES MARKET,

BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION)                 181

TABLE 178            REST OF ASIA PACIFIC: DIABETES CARE DEVICES MARKET,

BY DISEASE TYPE, 2023–2030 (USD MILLION)       181

TABLE 179            LATIN AMERICA: DIABETES CARE DEVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            182

TABLE 180            LATIN AMERICA: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            182

TABLE 181            LATIN AMERICA: DIABETES CARE DEVICES MARTKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)                183

TABLE 182            LATIN AMERICA: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 183

TABLE 183            LATIN AMERICA: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            183

TABLE 184            LATIN AMERICA: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION)                184

TABLE 185            LATIN AMERICA: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION)            184

TABLE 186            LATIN AMERICA: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            184

TABLE 187            BRAZIL: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            185

TABLE 188            BRAZIL: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 186

TABLE 189            BRAZIL: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES,

BY TYPE, 2023–2030 (USD MILLION)         186

TABLE 190            BRAZIL: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            186

TABLE 191            BRAZIL: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION)       187

TABLE 192            BRAZIL: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS,

2023–2030 (USD MILLION)            187

TABLE 193            BRAZIL: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            187

TABLE 194            MEXICO: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            188

TABLE 195            MEXICO: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)       189

TABLE 196            MEXICO: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES,

BY TYPE, 2023–2030 (USD MILLION)         189

TABLE 197            MEXICO: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            189

TABLE 198            MEXICO: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION)            190

TABLE 199            MEXICO: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS,

2023–2030 (USD MILLION)            190

TABLE 200            MEXICO: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            190

TABLE 201            REST OF LATIN AMERICA: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)            191

TABLE 202            REST OF LATIN AMERICA: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)    192

TABLE 203            REST OF LATIN AMERICA: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION)            192

TABLE 204            REST OF LATIN AMERICA: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)                 192

TABLE 205            REST OF LATIN AMERICA: INSULIN PENS MARKET, BY TYPE,

2023–2030 (USD MILLION)            193

TABLE 206            REST OF LATIN AMERICA: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION)            193

TABLE 207            REST OF LATIN AMERICA: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)                 193

TABLE 208            MIDDLE EAST & AFRICA: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)            195

TABLE 209            MIDDLE EAST & AFRICA: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)    195

TABLE 210            MIDDLE EAST & AFRICA: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION)            196

TABLE 211            MIDDLE EAST & AFRICA: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION)                 196

TABLE 212            MIDDLE EAST & AFRICA: INSULIN PENS MARKET, BY TYPE,

2023–2030 (USD MILLION)            196

TABLE 213            MIDDLE EAST & AFRICA: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION)            197

TABLE 214            MIDDLE EAST & AFRICA: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION)                 197

TABLE 215            GCC COUNTRIES: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2023–2030 (USD MILLION)            198

TABLE 216            GCC COUNTRIES: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION)                199

TABLE 217            GCC COUNTRIES: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 199

TABLE 218            GCC COUNTRIES: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            199

TABLE 219            GCC COUNTRIES: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION)                200

TABLE 220            GCC COUNTRIES: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION)            200

TABLE 221            GCC COUNTRIES: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2023–2030 (USD MILLION)            200

TABLE 222            MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN DIABETES CARE DEVICES MARKET, JANUARY 2022–AUGUST 2025        202

TABLE 223            DIABETES CARE DEVICES MARKET: DEGREE OF COMPETITION 204

TABLE 224            DIABETES CARE DEVICES MARKET: REGION FOOTPRINT       209

TABLE 225            DIABETES CARE DEVICES MARKET: PRODUCT TYPE FOOTPRINT            210

TABLE 226            DIABETES CARE DEVICES MARKET: PATIENT CARE SETTINGS FOOTPRINT     211

TABLE 227            DIABETES CARE DEVICES MARKET: DISEASE TYPE FOOTPRINT            212

TABLE 228            DIABETES CARE DEVICES MARKET: DETAILED LIST OF KEY

STARTUPS/SME PLAYERS             215

TABLE 229            DIABETES CARE DEVICES MARKET: COMPETITIVE BENCHMARKING

OF KEY STARTUPS/SME PLAYERS, BY PRODUCT TYPE AND REGION                215

TABLE 230            DIABETES CARE DEVICES MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022– JUNE 2025                 218

TABLE 231            DIABETES CARE DEVICES MARKET: DEALS, JANUARY 2022– JUNE 2025             219

TABLE 232            DIABETES CARE DEVICES MARKET: EXPANSIONS, JANUARY 2022– JUNE 2025                 220

TABLE 233            DIABETES CARE DEVICES MARKET: OTHER DEVELOPMENTS,

JANUARY 2022– JUNE 2025             220

TABLE 234            F. HOFFMAN-LA ROCHE LTD.: COMPANY OVERVIEW          221

TABLE 235            F. HOFFMAN-LA ROCHE LTD.: PRODUCTS/SOLUTIONS OFFERED          222

TABLE 236            F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025                 223

TABLE 237            F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022–AUGUST 2025       224

TABLE 238            F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2022–AUGUST 2025       224

TABLE 239            ABBOTT: COMPANY OVERVIEW                226

TABLE 240            ABBOTT: PRODUCTS/SOLUTIONS OFFERED                 228

TABLE 241            ABBOTT: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025       229

TABLE 242            ABBOTT: DEALS, JANUARY 2022–AUGUST 2025                 230

TABLE 243            ABBOTT: EXPANSIONS, JANUARY 2022–AUGUST 2025        231

TABLE 244            ABBOTT: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025           231

TABLE 245            DEXCOM, INC.: COMPANY OVERVIEW   233

TABLE 246            DEXCOM, INC.: PRODUCTS/SOLUTIONS OFFERED             234

TABLE 247            DEXCOM, INC.: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2022–AUGUST 2025       235

TABLE 248            DEXCOM, INC.: DEALS, JANUARY 2022–AUGUST 2025        236

TABLE 249            DEXCOM, INC.: EXPANSIONS, JANUARY 2022–AUGUST 2025     236

TABLE 250            MEDTRONIC: COMPANY OVERVIEW       238

TABLE 251            MEDTRONIC: PRODUCTS/SOLUTIONS OFFERED             239

TABLE 252            MEDTRONIC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025            240

TABLE 253            MEDTRONIC: DEALS, JANUARY 2022–AUGUST 2025        241

TABLE 254            MEDTRONIC: EXPANSIONS, JANUARY 2022–AUGUST 2025     242

TABLE 255            MEDTRONIC: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025       242

TABLE 256            B. BRAUN SE: COMPANY OVERVIEW       244

TABLE 257            B. BRAUN SE: PRODUCTS/SOLUTIONS OFFERED                 245

TABLE 258            EMBECTA CORP.: COMPANY OVERVIEW                 247

TABLE 259            EMBECTA CORP.: PRODUCTS/SOLUTIONS OFFERED             249

TABLE 260            EMBECTA CORP.: PRODUCTS APPROVALS, JANUARY 2022–AUGUST 2025       249

TABLE 261            EMBECTA CORP.: DEALS, JANUARY 2022–AUGUST 2025     249

TABLE 262            EMBECTA CORP.: EXPANSIONS, JANUARY 2022–AUGUST 2025     250

TABLE 263            EMBECTA CORP.: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025       250

TABLE 264            NIPRO: COMPANY OVERVIEW   251

TABLE 265            NIPRO: PRODUCTS/SOLUTIONS OFFERED                 252

TABLE 266            NIPRO: EXPANSIONS, JANUARY 2022–AUGUST 2025        253

TABLE 267            SENSEONICS: COMPANY OVERVIEW       254

TABLE 268            SENSEONICS: PRODUCTS/SOLUTIONS OFFERED             255

TABLE 269            SENSEONICS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025            256

TABLE 270            SENSEONICS: DEALS, JANUARY 2022–AUGUST 2025        256

TABLE 271            SENSEONICS: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025       257

TABLE 272            YPSOMED: COMPANY OVERVIEW             258

TABLE 273            YPSOMED: PRODUCTS/SOLUTIONS OFFERED                 259

TABLE 274            YPSOMED: PRODUCTS LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025            260

TABLE 275            YPSOMED: DEALS, JANUARY 2022–AUGUST 2025                 261

TABLE 276            YPSOMED: EXPANSIONS, JANUARY 2022–AUGUST 2025     262

TABLE 277            YPSOMED: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025           263

TABLE 278            I-SENS, INC.: COMPANY OVERVIEW         264

TABLE 279            I-SENS, INC.: PRODUCTS/SOLUTIONS OFFERED                 265

TABLE 280            I-SENS, INC.: PRODUCTS APPROVALS, JANUARY 2022–AUGUST 2025           266

TABLE 281            I-SENS, INC.: DEALS, JANUARY 2022–AUGUST 2025        266

TABLE 282            TANDEM DIABETES CARE, INC.: COMPANY OVERVIEW          267

TABLE 283            TANDEM DIABETES CARE, INC.: PRODUCTS/SOLUTIONS OFFERED          268

TABLE 284            TANDEM DIABETES CARE, INC.: PRODUCTS LAUNCHES & APPROVALS,

JANUARY 2022–AUGUST 2025       269

TABLE 285            TANDEM DIABETES CARE, INC.: DEALS, JANUARY 2022–AUGUST 2025       270

TABLE 286            INSULET CORPORATION: COMPANY OVERVIEW                 272

TABLE 287            INSULET CORPORATION: PRODUCTS/SOLUTIONS OFFERED          273

TABLE 288            INSULET CORPORATION: PRODUCTS LAUNCHES & APPROVALS,

JANUARY 2022–AUGUST 2025       274

TABLE 289            INSULET CORPORATION: DEALS, JANUARY 2022–AUGUST 2025           276

TABLE 290            INSULET CORPORATION: EXPANSIONS, JANUARY 2022–AUGUST 2025       276

TABLE 291            INSULET CORPORATION: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025  277

TABLE 292            ACON LABORATORIES, INC.: COMPANY OVERVIEW          278

TABLE 293            ACON LABORATORIES, INC.: PRODUCTS/SOLUTIONS OFFERED          278

TABLE 294            ARKRAY, INC.: COMPANY OVERVIEW     280

TABLE 295            ARKRAY, INC.: PRODUCTS/SOLUTIONS OFFERED             280

TABLE 296            ARKRAY, INC.: PRODUCTS LAUNCHES, JANUARY 2022–AUGUST 2025           281

TABLE 297            TERUMO CORPORATION: COMPANY OVERVIEW          282

TABLE 298            TERUMO CORPORATION: PRODUCTS/SOLUTIONS OFFERED          283

TABLE 299            TERUMO CORPORATION: PRODUCTS LAUNCHES, JANUARY 2022–AUGUST 2025              284

TABLE 300            TERUMO CORPORATION: DEALS, JANUARY 2022–AUGUST 2025           284

TABLE 301            TERUMO CORPORATION: EXPANSIONS, JANUARY 2022–AUGUST 2025       285

TABLE 302            TERUMO CORPORATION: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025  285

TABLE 303            SINOCARE: COMPANY OVERVIEW            286

TABLE 304            AGAMATRIX: COMPANY OVERVIEW        288

TABLE 305            LIFESCAN IP HOLDINGS, LLC: COMPANY OVERVIEW          289

TABLE 306            SD BIOSENSOR, INC.: COMPANY OVERVIEW                 290

TABLE 307            DEBIOTECH S.A.: COMPANY OVERVIEW                 291

TABLE 308            SUNGSHIM MEDICAL CO., LTD.: COMPANY OVERVIEW          292

TABLE 309            SOOIL DEVELOPMENTS CO., LTD.: COMPANY OVERVIEW          293

TABLE 310            HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.: COMPANY OVERVIEW       294

TABLE 311            MICROGENE DIAGNOSTIC SYSTEMS (P) LTD.: COMPANY OVERVIEW   295

TABLE 312            ROSSMAX INTERNATIONAL LTD.: COMPANY OVERVIEW          296

LIST OF FIGURES

FIGURE 1              DIABETES CARE DEVICES MARKET SEGMENTATION & REGIONAL SCOPE    30

FIGURE 2              DIABETES CARE DEVICES MARKET: YEARS CONSIDERED    32

FIGURE 3              DIABETES CARE DEVICES MARKET: RESEARCH DESIGN                35

FIGURE 4              DIABETES CARE DEVICES MARKET: KEY DATA FROM SECONDARY SOURCES    37

FIGURE 5              DIABETES CARE DEVICES MARKET: KEY PRIMARY SOURCES

(SUPPLY AND DEMAND SIDES) 37

FIGURE 6              DIABETES CARE DEVICES MARKET: KEY DATA FROM PRIMARY SOURCES            38

FIGURE 7              DIABETES CARE DEVICES MARKET: KEY INSIGHTS FROM INDUSTRY EXPERTS     39

FIGURE 8              BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS     39

FIGURE 9              BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,

DESIGNATION, AND REGION     40

FIGURE 10            DIABETES CARE DEVICES MARKET SIZE ESTIMATION: REVENUE

SHARE ANALYSIS (2024) 41

FIGURE 11            DIABETES CARE DEVICES MARKET: REVENUE SHARE ANALYSIS

FOR ABBOTT (US) (2024)               41

FIGURE 12            SUPPLY-SIDE ANALYSIS OF DIABETES CARE DEVICES MARKET (2024)               42

FIGURE 13            DIABETES CARE DEVICES MARKET: CAGR PROJECTIONS (SUPPLY-SIDE ANALYSIS)               42

FIGURE 14            DIABETES CARE DEVICES MARKET: BOTTOM-UP APPROACH  43

FIGURE 15            CAGR PROJECTIONS FROM DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES ANALYSIS IN DIABETES CARE DEVICES MARKET (2025–2030)  44

FIGURE 16            DIABETES CARE DEVICES MARKET: TOP-DOWN APPROACH         45

FIGURE 17            DIABETES CARE DEVICES MARKET: DATA TRIANGULATION             46

FIGURE 18            DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE,

2025 VS. 2030 (USD MILLION)      49

FIGURE 19            DIABETES CARE DEVICES MARKET, BY DISEASE TYPE,

2025 VS. 2030 (USD MILLION)      50

FIGURE 20            DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS,

2025 VS. 2030 (USD MILLION)      50

FIGURE 21            REGIONAL SNAPSHOT OF DIABETES CARE DEVICES MARKET            51

FIGURE 22            TECHNOLOGICAL ADVANCEMENTS IN DIABETES CARE DEVICES TO DRIVE MARKET    52

FIGURE 23            CHINA AND BLOOD GLUCOSE MONITORING SYSTEMS COMMNADED LARGEST ASIA PACIFIC MARKET SHARE IN 2024  53

FIGURE 24            JAPAN TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD       54

FIGURE 25            ASIA PACIFIC TO REGISTER HIGHEST CAGR FROM 2025 TO 2030          54

FIGURE 26            EMERGING MARKETS TO ACCOUNT FOR HIGHER GROWTH RATES

DURING STUDY PERIOD               55

FIGURE 27            DIABETES CARE DEVICES MARKET: DRIVERS, RESTRAINTS,

OPPORTUNITIES, AND CHALLENGES     56

FIGURE 28            DIABETES CARE DEVICES MARKET: ECOSYSTEM ANALYSIS            64

FIGURE 29            DIABETES CARE DEVICES MARKET: VALUE CHAIN ANALYSIS              66

FIGURE 30            DIABETES CARE DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 67

FIGURE 31            INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER               69

FIGURE 32            KEY BUYING CRITERIA FOR MAJOR END USERS                 70

FIGURE 33            TOP PATENT APPLICANTS/OWNERS (COMPANIES/INSTITUTES) FOR DIABETES CARE DEVICES MARKET (JANUARY 2014–DECEMBER 2024)           77

FIGURE 34            TOP PATENT APPLICANT COUNTRIES FOR PATENTS ON DIABETES CARE DEVICES (JANUARY 2014–DECEMBER 2024)              78

FIGURE 35            ADJACENT MARKETS TO DIABETES CARE DEVICES MARKET            79

FIGURE 36            DIABETES CARE DEVICES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES                 80

FIGURE 37            IMPACT OF AI/GEN AI ON DIABETES CARE DEVICES MARKET            82

FIGURE 38            FUNDING AND NUMBER OF DEALS IN DIABETES CARE DEVICES MARKET, 2019–2023 (USD MILLION)         84

FIGURE 39            GEOGRAPHIC SNAPSHOT OF DIABETES CARE DEVICES MARKET            127

FIGURE 40            NORTH AMERICA: DIABETES CARE DEVICES MARKET SNAPSHOT       129

FIGURE 41            ASIA PACIFIC: DIABETES CARE DEVICES MARKET SNAPSHOT       160

FIGURE 42            REVENUE SHARE ANALYSIS OF KEY PLAYERS IN DIABETES

CARE DEVICES MARKET (2020–2024)        203

FIGURE 43            MARKET SHARE ANALYSIS OF KEY PLAYERS IN DIABETES CARE

DEVICES MARKET (2024)               204

FIGURE 44            DIABETES CARE DEVICES MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2024       207

FIGURE 45            DIABETES CARE DEVICES MARKET: COMPANY FOOTPRINT       208

FIGURE 46            DIABETES CARE DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 214

FIGURE 47            EV/EBITDA OF KEY VENDORS   216

FIGURE 48            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA

OF KEY VENDORS            216

FIGURE 49            DIABETES CARE DEVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS     217

FIGURE 50            R&D EXPENDITURE OF KEY PLAYERS IN DIABETES CARE DEVICES MARKET

(2022–2024)          218

FIGURE 51            F. HOFFMAN-LA ROCHE LTD.: COMPANY SNAPSHOT          222

FIGURE 52            ABBOTT: COMPANY SNAPSHOT                227

FIGURE 53            DEXCOM, INC.: COMPANY SNAPSHOT   234

FIGURE 54            MEDTRONIC: COMPANY SNAPSHOT      239

FIGURE 55            B. BRAUN SE: COMPANY SNAPSHOT       244

FIGURE 56            EMBECTA CORP.: COMPANY SNAPSHOT                 248

FIGURE 57            NIPRO: COMPANY SNAPSHOT   252

FIGURE 58            SENSEONICS: COMPANY SNAPSHOT       255

FIGURE 59            YPSOMED: COMPANY SNAPSHOT            259

FIGURE 60            I-SENS, INC.: COMPANY SNAPSHOT         264

FIGURE 61            TANDEM DIABETES CARE, INC.: COMPANY SNAPSHOT          268

FIGURE 62            INSULET CORPORATION: COMPANY SNAPSHOT          273

FIGURE 63            TERUMO CORPORATION: COMPANY SNAPSHOT          283

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧